Anthera Pharmaceuticals Inc  

(Public, NASDAQ:ANTH)   Watch this stock  
Find more results for Debra Adams�
-0.05 (-1.94%)
Real-time:   10:01AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.53 - 2.59
52 week 2.51 - 4.26
Open 2.58
Vol / Avg. 6,666.00/146,786.00
Mkt cap 57.47M
P/E     -
Div/yield     -
EPS -3.62
Shares 22.64M
Beta 1.53
Inst. own 57%
Oct 27, 2014
Q3 2014 Anthera Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 28, 2014
Jul 15, 2014
Anthera Pharmaceuticals Inc Acquires Sollpura (liprotamase) from Eli Lilly and Company
Jun 10, 2014
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets - -96.65%
Return on average equity - -549.52%
Employees 25 -
CDP Score - -


Suite B, 25801 Industrial Blvd
United States - Map
+1-510-8565600 (Phone)
+1-510-8565597 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Anthera Pharmaceuticals, Inc., is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. The Company�s Phase III candidate, blisibimod, targets B-cell activating factor (BAFF), which has been elevated in a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, (lupus), Immunoglobin A nephropathy (IgA nephropathy), lupus nephritis, vasculitis and others. BAFF, also known as BLyS, is a tumor necrosis family member and is critical to the development, maintenance and survival of multiple B-cell lineages, as well as plasma cells. B-cells and plasma cells are a vital part of the human immune system, producing natural antibody responses to invading pathogens, such as viruses. In July 2014, Anthera Pharmaceuticals Inc acquired Sollpura (liprotamase), a investigational Pancreatic Enzyme Replacement Therapy (PERT) from Eli Lilly and Company.

Officers and directors

Christopher S. Henney Ph.D. Independent Chairman of the Board
Age: 73
Bio & Compensation  - Reuters
Paul F. Truex President, Chief Executive Officer, Director
Age: 45
Bio & Compensation  - Reuters
May Liu Senior Vice President - Finance and Administration, Principal Accounting Officer
Age: 38
Bio & Compensation  - Reuters
Debra Odink Ph.D. Senior Vice President, Chief Technology Officer
Age: 50
Bio & Compensation  - Reuters
Paula Adams Ph.D. Senior Vice President - Global Regulatory Affairs and Compliance
Age: 50
Bio & Compensation  - Reuters
Colin Hislop M.D. Senior Vice President, Chief Medical Officer
Age: 56
Bio & Compensation  - Reuters
Brian R. Mueller Director
Age: 40
Bio & Compensation  - Reuters
Philip T. Sager M.D. Director
Bio & Compensation  - Reuters
Steven B. Engle Independent Director
Age: 59
Bio & Compensation  - Reuters
David E. Thompson Independent Director
Age: 66
Bio & Compensation  - Reuters